Search

Your search keyword '"R, Alejandro"' showing total 236 results

Search Constraints

Start Over You searched for: Author "R, Alejandro" Remove constraint Author: "R, Alejandro" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
236 results on '"R, Alejandro"'

Search Results

2. Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis

3. Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study

4. Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a CCC19 registry analysisImpact of B-cell malignancy therapy on COVID-19 outcomes

5. Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency

6. Impact of race and ethnicity on early mortality in multiple myeloma: a SEER analysis

7. Efficacy and safety of CAR-T cell therapy in minorities

9. Whole-genome landscape of adult T-cell leukemia/lymphoma

10. Autologous stem cell transplantation in an older adult population

12. A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort

16. TCL-150 Outcome of Stem Cell Transplantation in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma

17. ABCL-161 Reasons for Non-Referral for Autologous Stem Cell Transplantation in Central Nervous System Lymphoma (CNSL) Patients in a Minority-Rich, Multiracial, and Underprivileged Population at Montefiore Medical Center, Albert Einstein College of Medicine

19. POSTER: ALL-040 Hispanic Patients With T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Had Worse Overall Survival in a Minority Predominant Cohort

20. POSTER: MM-413 Early Mortality in Multiple Myeloma- a SEER Data Analysis

21. ALL-040 Hispanic Patients With T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Had Worse Overall Survival in a Minority Predominant Cohort

22. MM-413 Early Mortality in Multiple Myeloma- a SEER Data Analysis

23. Data from A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML

24. Table S1 from A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML

25. Primary central nervous system lymphoma: treatment access and outcomes in HIV positive patients in a minority rich cohort

26. Improving Unrelated Donor Equity: Assessing Mismatched Donor Opportunities with Real-World Data in a Minority-Predominant Cohort

27. Clinicopathologic characterization of cutaneous adult T-cell leukemia/lymphoma: A single tertiary care center experience in the United States.

28. Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial

29. A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML

30. Allogeneic but Not Autologous Stem Cell Transplantation Improves Outcome in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma

31. Outcomes of Autologous Stem Cell Transplantation for Relapsed DLBCL in Single Center Serving a Minority Population

33. Resistance to CD19 Immunotherapy in B-Cell ALL Is Associated with Loss of CD19 and CD22 and an Enhanced Vulnerability to B Cell Receptor Signaling Inhibition

34. Outcomes Analysis of T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-ALL/T-LBL) in a Minority Rich Cohort

35. Supplementary Figure from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

36. Data from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

37. Supplementary Tables S1-S5 from Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial

38. Supplementary Figures S1-S2 from Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial

39. Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents

40. Data from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

41. Supplementary Figure from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

42. Supplementary Figures S1-S2 from Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial

43. Data from Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial

44. Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents

45. COVID-19 in Patients with Hematologic Malignancies: Outcomes and Options for Treatments

46. A Co-Management Model For Myeloid Malignancies that Evolved During the COVID-19 Pandemic

47. A Non-Cytotoxic Regimen Using a Weekly Low Dose Decitabine and Venetoclax for MDS and AML in a Real World Cohort

48. Barriers to Autologous Stem Cell Transplantation As Consolidation for Primary Central Nervous System Lymphoma (PCNSL) in HIV Positive Patients in a Minority Rich Cohort in the Bronx, New York

49. Resistance to CD19 Immunotherapy in B-Cell ALL Is Associated with Loss of CD19 and CD22 and an Enhanced Vulnerability to B Cell Receptor Signaling Inhibition

50. Outcomes of Autologous Stem Cell Transplantation for Relapsed DLBCL in Single Center Serving a Minority Population

Catalog

Books, media, physical & digital resources